FNY Partners Fund LP grew its stake in Qiagen N.V. (NASDAQ:QGEN) by 272.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 43,403 shares of the company’s stock after purchasing an additional 31,749 shares during the quarter. FNY Partners Fund LP’s holdings in Qiagen were worth $1,367,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of QGEN. Acrospire Investment Management LLC raised its stake in shares of Qiagen by 11.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 3,344 shares of the company’s stock valued at $112,000 after purchasing an additional 349 shares during the period. Oppenheimer Asset Management Inc. raised its stake in shares of Qiagen by 0.5% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 3,961 shares of the company’s stock valued at $133,000 after purchasing an additional 20 shares during the period. Quadrant Capital Group LLC raised its stake in shares of Qiagen by 4.1% in the 2nd quarter. Quadrant Capital Group LLC now owns 5,742 shares of the company’s stock valued at $183,000 after purchasing an additional 225 shares during the period. Quantitative Systematic Strategies LLC acquired a new stake in shares of Qiagen in the 2nd quarter valued at about $211,000. Finally, Koch Industries Inc. acquired a new stake in shares of Qiagen in the 2nd quarter valued at about $231,000. 62.37% of the stock is currently owned by institutional investors.
Qiagen N.V. (QGEN) opened at $31.02 on Wednesday. Qiagen N.V. has a 1-year low of $27.51 and a 1-year high of $36.34. The company has a current ratio of 5.33, a quick ratio of 4.78 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $7,112.11, a PE ratio of 25.40, a P/E/G ratio of 1.91 and a beta of 1.10.
Qiagen (NASDAQ:QGEN) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.32 EPS for the quarter, hitting analysts’ consensus estimates of $0.32. Qiagen had a return on equity of 11.36% and a net margin of 6.40%. The business had revenue of $364.00 million during the quarter, compared to analysts’ expectations of $363.42 million. During the same quarter last year, the company posted $0.29 earnings per share. Qiagen’s quarterly revenue was up 7.5% on a year-over-year basis. analysts forecast that Qiagen N.V. will post 1.25 EPS for the current fiscal year.
Several analysts have issued reports on QGEN shares. Zacks Investment Research downgraded Qiagen from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. Deutsche Bank reissued a “buy” rating on shares of Qiagen in a research note on Wednesday, November 8th. TheStreet raised Qiagen from a “c+” rating to a “b+” rating in a research note on Tuesday, November 7th. Commerzbank reissued a “buy” rating on shares of Qiagen in a research note on Tuesday, November 7th. Finally, Cowen restated a “hold” rating and issued a $33.00 price objective on shares of Qiagen in a report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $34.06.
ILLEGAL ACTIVITY WARNING: This news story was first reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://ledgergazette.com/2017/12/06/qiagen-n-v-qgen-shares-bought-by-fny-partners-fund-lp.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen N.V. and related companies with MarketBeat.com's FREE daily email newsletter.